Sudden Gains in Internet-Based Cognitive Behavior Therapy for Body Dysmorphic Disorder.

body dysmorphic disorder clinical trials cognitive-behavior therapy sudden gains treatment response

Journal

Behavior therapy
ISSN: 1878-1888
Titre abrégé: Behav Ther
Pays: England
ID NLM: 1251640

Informations de publication

Date de publication:
09 2020
Historique:
received: 29 08 2019
revised: 31 10 2019
accepted: 08 11 2019
entrez: 18 8 2020
pubmed: 18 8 2020
medline: 5 2 2021
Statut: ppublish

Résumé

Sudden gains have been associated with better short- and long-term treatment outcomes in a number of psychiatric disorders. However, no studies to date have evaluated sudden gains in body dysmorphic disorder (BDD). We used data from a previous randomized controlled trial evaluating the efficacy of an Internet-based cognitive-behavior treatment (CBT) for BDD. The sample consisted of 47 adults diagnosed with BDD. We compared the treatment outcomes of sudden gainers vs. gradual gainers (i.e., treatment responders with no sudden gains) and non-sudden gainers (i.e., gradual gainers plus nonresponders) at posttreatment and 3, 12, and 24 months after the end of the treatment. Twelve (25.5%) participants experienced a sudden gain. Compared to non-sudden gainers and to gradual gainers, sudden gainers showed significantly larger improvements on the Yale-Brown Obsessive-Compulsive Scale modified for BDD at posttreatment (g = 1.23 and g = .91, respectively), and at 3-month (g = 1.23 and g = 1.00, respectively), 12-month (g = 1.12 and g = .91, respectively), and 24-month follow-up (g = 1.11 and g = .97, respectively). This translated into higher rates of treatment responders and remitters in the sudden gainers across all time points. The occurrence of sudden gains in Internet-based CBT for BDD is associated with favorable short- and long-term treatment outcomes. This suggests that a sudden improvement during the treatment could be a marker of good prognosis, while non-sudden-including gradual-gainers are more likely to need continued support or booster sessions. Early identification of patients who are not progressing as expected and subsequent tailoring of the delivered intervention has the potential to improve treatment outcomes in this group.

Identifiants

pubmed: 32800303
pii: S0005-7894(19)30136-4
doi: 10.1016/j.beth.2019.11.002
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

753-763

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Conflict of Interest Statement Johan Bjureberg and Erik Andersson receive book royalties from Natur & Kultur. Christian Rück is a consultant for the Swedish Transport Agency and receives book royalties from Studentlitteratur. Lorena Fernández de la Cruz receives royalties for contributing articles to UpToDate, Wolters Kluwer Health. All other authors report no conflicts of interest.

Auteurs

Johan Bjureberg (J)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet; Stockholm Health Care Services, Stockholm County Council, Stockholm.

Jesper Enander (J)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet.

Erik Andersson (E)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet.

Volen Z Ivanov (VZ)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet; Stockholm Health Care Services, Stockholm County Council, Stockholm.

Christian Rück (C)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet; Stockholm Health Care Services, Stockholm County Council, Stockholm.

Lorena Fernández de la Cruz (L)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet; Stockholm Health Care Services, Stockholm County Council, Stockholm. Electronic address: lorena.fernandez.de.la.cruz@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH